Development of a hyperbranched polymer-based methotrexate nanomedicine for rheumatoid arthritis
Source abstract
Abstract
Methotrexate (MTX) is an effective disease modifying anti-rheumatic drug, but can cause significant hepatotoxicity and liver failure in some individuals. The goal of this work was to develop a MTX-conjugated hyperbranched polymeric nanoparticle based on oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and examine its ability to selectively deliver MTX to rheumatic joints while sparing the liver. MTX was conjugated to the hyperbranched polymer via a matrix metalloproteinase-13 cleavable peptide linker. Two populations of nanoparticles were produced, with sizes averaging 20 and 200nm. Tri-peptide (FFK)-modified MTX was liberated in the presence of matrix metalloproteinase 13 (MMP-13)and showed 100 to 1000-fold lower antiproliferative capacity in monocytic THP-1 cells compared to unmodified MTX, depending on whether the gamma-carboxylate of MTX was functionalized with O-tert-butyl. Nanoparticles showed prolonged plasma exposure after intravenous injection with a terminal half-life of approximately 1 day, but incomplete (50%) absorption after subcutaneous administration. Nanoparticles selectively accumulated in inflamed joints in a rat model of rheumatoid arthritis and showed less than 5% biodistribution in the liver after 5 days. MTX-OtBu nanoparticles also showed no hepatocellular toxicity at 500 μM MTX equivalents. This work provides support for the further development of OEGMA-based hyperbranched polymers as MTX drug delivery systems for rheumatoid arthritis. STATEMENT OF SIGNIFICANCE: Nanomedicines containing covalently conjugated methotrexate offer the potential for selective accumulation of the potent hepatotoxic drug in rheumatic joints and limited liver exposure. One limitation of the high surface presentation of methotrexate on a nanoparticle surface, however, is the potential for enhanced liver uptake. We developed several OEGMA-based hyperbranched polymers containing alpha-carboxyl modified and unmodified methotrexate conjugated via an MMP-13 cleavable hexapeptide linker. The modified methotrexate polymer showed promising in vitro and in vivo behavior warranting further development and optimization as an anti-rheumatic nanomedicine. This work presents a new avenue for further research into the development of hyperbranched polymers for rheumatoid arthritis and suggests interesting approaches that may overcome some limitations associated with the translation of anti-rheumatic nanomedicines into patients.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Rheumatoid Arthritis Research and Therapies · Multiple Myeloma Research and Treatments · Chronic Myeloid Leukemia Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies10.1038/s41413-018-0016-9 ↗
2. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases10.1038/nrrheum.2016.178 ↗
3. Methotrexate and its mechanisms of action in inflammatory arthritis10.1038/s41584-020-0373-9 ↗
4. Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1beta on rheumatoid arthritis fibroblast-like synoviocytes10.1186/s13075-018-1554-7 ↗
5. Methotrexate mechanism in treatment of rheumatoid arthritis10.1016/j.jbspin.2018.07.004 ↗
6. Assessment of liver fibrosis markers in people with rheumatoid arthritis on methotrexate
7. Nanomedicine delivers promising treatments for rheumatoid arthritis10.2217/nnm.15.45 ↗
8. Increased encapsulation efficiency of methotrexate in liposomes for rheumatoid arthritis therapy10.3390/biomedicines8120630 ↗
9. Endogenous sialic acid-engineered micelles: a multifunctional platform for on-demand methotrexate delivery and bone repair of rheumatoid arthritis10.1039/C7NR08430G ↗
10. SPECT imaging and highly efficient therapy of rheumatoid arthritis based on hyperbranched semiconducting polymer nanoparticles10.1039/D0BM02037K ↗
11. Rational design of metal-organic frameworks to deliver methotrexate for targeted rheumatoid arthritis therapy10.1016/j.jconrel.2020.10.069 ↗
12. Optimization and development of methotrexate- and resveratrol-loaded nanoemulsion formulation using box-Behnken design for rheumatoid arthritis10.1089/adt.2020.989 ↗
13. Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model
14. Folate receptor-targeted dendrimer-methotrexate conjugate for inflammatory arthritis10.1166/jbn.2015.2077 ↗
15. Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models10.1186/s13075-016-0971-8 ↗
16. Near-infrared fluorescence imaging-guided focused ultrasound-mediated therapy against rheumatoid arthritis by MTX-ICG-loaded iRGD-modified echogenic liposomes10.7150/thno.44865 ↗
17. Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity10.2147/IJN.S25310 ↗
18. Nanosized drug delivery vectors and the reticuloendothelial system
19. Capping methotrexate alpha-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers10.1021/mp1001872 ↗
20. Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats10.1021/mp500531e ↗
21. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers10.1021/mp900049a ↗
22. The impact of polymer size and cleavability on the intravenous pharmacokinetics of PEG-based hyperbranched polymers in rats10.3390/nano10122452 ↗
23. The enhancement of chondrogenic differentiation of human mesenchymal stem cells by enzymatically regulated RGD functionalities10.1016/j.biomaterials.2008.01.035 ↗
24. Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis
25. Expression of matrix metalloproteinase-13 and tissue inhibitor of metalloproteinase-1 in acute liver injury10.1016/S0168-8278(99)80100-7 ↗
26. Bioinspired shielding strategies for nanoparticle drug delivery applications10.1021/acs.molpharmaceut.8b00292 ↗
27. Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system10.1002/anie.201002221 ↗
28. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX10.1021/bc0499174 ↗
29. The differential cytotoxicity of methotrexate in rat hepatocyte monolayer and spheroid cultures10.1016/S0887-2333(00)00036-9 ↗
30. Characterisation and pharmacological sensitivity of antigen arthritis induced by methylated bovine serum albumin in the rat10.1007/BF01990957 ↗
31. Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate10.1016/j.trsl.2018.04.001 ↗
32. Low-fouling fluoropolymers for bioconjugation and in vivo tracking10.1002/anie.201914119 ↗
33. Proteins conjugated with sulfoxide-containing polymers show reduced macrophage cellular uptake and improved pharmacokinetics10.1021/acsmacrolett.0c00291 ↗
34. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel10.1016/j.cmpb.2010.01.007 ↗
35. Terminal functional glycopolymers via a combination of catalytic chain transfer polymerisation (CCTP) followed by three consecutive click reactions10.1039/c2py20013a ↗
36. Precision self-assembly of amphiphilic random copolymers into uniform and self-sorting nanocompartments in water10.1021/acs.macromol.6b01085 ↗
37. Enhanced toxicity and cellular uptake of methotrexate-conjugated nanoparticles in folate receptor-positive cancer cells by decorating with folic acid-conjugated d-alpha-tocopheryl polyethylene glycol 1000 succinate10.1016/j.colsurfb.2015.09.013 ↗
38. Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid10.1186/1471-2474-13-126 ↗
39. Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-110.1186/1471-2121-6-25 ↗
40. Liver as a key organ in the supply, storage, and excretion of copper10.1093/ajcn/88.3.851S ↗
41. Current perspectives on (89)Zr-PET Imaging10.3390/ijms21124309 ↗